Disease · HP_0000505
Visual impairment
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Visual impairment. Diseases, record HP_0000505. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000505
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Visual impairment
- Open Targets ID
- HP_0000505
- Other names
- Impaired vision, Loss of eyesight, Poor vision
- Highest stage of its drugs
- Phase 3, for 4 of its 9 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AFLIBERCEPT | CHEMBL1742982 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| RANIBIZUMAB | CHEMBL1201825 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| RUBOXISTAURIN | CHEMBL91829 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VERTEPORFIN | CHEMBL5314346 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VATIQUINONE | CHEMBL1812161 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEXTROSE | CHEMBL1222250 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN HUMAN | CHEMBL1201631 | Protein | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LUTEIN | CHEMBL173929 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ZEAXANTHIN | CHEMBL2359248 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets5
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | 2 | Vascular endothelial growth factor A inhibitor | Phase 3 | https://conductscience.org/library/genes/7422 | Drugs and targets |
| INSR | Insulin receptor | 1 | Insulin receptor agonist | Unknown | https://conductscience.org/library/genes/3643 | Drugs and targets |
| NQO1 | NAD(P)H dehydrogenase [quinone] 1 | 1 | Quinone reductase 1 modulator | Phase 2 | https://conductscience.org/library/genes/1728 | Drugs and targets |
| PGF | Placenta growth factor | 1 | Placenta growth factor inhibitor | Phase 3 | https://conductscience.org/library/genes/5228 | Drugs and targets |
| PRKCB | Protein kinase C beta type | 1 | Protein kinase C beta inhibitor | Phase 3 | https://conductscience.org/library/genes/5579 | Drugs and targets |
Trials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01922102 | Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia | Phase 3 | 457 | 2019-06-24 | Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM) | RANIBIZUMAB, VERTEPORFIN | Its record names the disease | ClinicalTrials.gov |
| NCT00266695 | Treatment for Completers of the Study B7A-MC-MBCM | Phase 3 | 203 | 2016-01-28 | Diabetic Retinopathy | RUBOXISTAURIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02034006 | A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. | Phase 3 | 200 | 2019-02-18 | Choroidal Neovascularization Secondary to Pathologic Myopia | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02850263 | A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema | 750 | Macular Edema | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov | ||
| NCT03530189 | Outcome of Very Preterm Infants With Glucose Level Disturbances | 150 | Cerebral Palsy Infantile | DEXTROSE, INSULIN HUMAN | Its record names the disease | ClinicalTrials.gov | ||
| NCT04288232 | Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan | Phase 3 | 45 | Center-involved Diabetic Macular Edema | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov | |
| NCT06391411 | Effect of Micronutrient Supplementation on the Intestinal Microbiota in Patients With Age-related Macular Degeneration - The Gut-Retina-axis Study | Not applicable | 45 | Age-Related Macular Degeneration | LUTEIN, ZEAXANTHIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01793090 | EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological Impairment | Phase 2 | 30 | Methylmalonic Aciduria and Homocystinuria,Cblc Type, Genetic Disease, Retinopathy | VATIQUINONE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials16
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000505
GET https://conductscience.org/api/diseases/v1/HP_0000505/drugs